KoKo

Executive Summary

KoKo is a UK-based medical technology company specializing in high-accuracy pulmonary function testing (PFT) equipment and integrated software solutions. Founded in 2012, the company offers FDA-approved spirometers, respirometers, and comprehensive PFT systems that are ATS/ERS-compliant, enhancing clinical workflow and EMR interoperability. KoKo's solutions are designed to reduce total cost of care while delivering reliable test results, positioning the company as a key player in the respiratory diagnostics market. With a focus on improving clinical efficiency, KoKo serves hospitals, clinics, and pulmonary practices globally. KoKo has established a strong foothold in the PFT market, leveraging its proprietary KoKo Smart platform to differentiate from competitors. The company benefits from increasing demand for accurate respiratory diagnostics due to the rising prevalence of COPD, asthma, and post-COVID lung health monitoring. While privately held with no disclosed valuation, KoKo's FDA approvals and established product portfolio suggest a solid market position. Growth opportunities lie in expanding into emerging markets, launching next-generation devices, and deepening software integration with electronic health records. However, the niche market and competition from larger medtech firms pose challenges. Overall, KoKo demonstrates steady potential for gradual expansion.

Upcoming Catalysts (preview)

• Q1 2027Launch of Next-Generation Spirometer with Enhanced AI Analytics80% success
• Q4 2026Strategic Partnership with Major EMR Provider for Seamless Integration60% success
• Q2 2026FDA Clearance for Portable PFT Device for Home Monitoring70% success